Drug shortages–a critical challenge for the generic-drug market
Abstract
To address the growing U.S. shortages of critical generic drugs, long-term remedies, both legislative and regulatory, must be considered. Some basic changes in generic-drug law and FDA practices and greater financial incentives for manufacturing generics may be key.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The growing cancer survivor population will strain a healthcare system with frequent cancer drug shortages and oncology demand that is expected to exceed oncologist supply.
“The growing population of cancer survivors will put pressure on a healthcare system in which cancer drug shortages are increasingly common and the demand for oncology services is poised to outpace the supply of oncologists (4–6).”
From Cancer Survivors in the United States: Prevalence across the Survivorship Trajectory and Implications for Care (2013) · cites this paper as [5]
Cited by
Sorted by citations
de Moor, J. S., Mariotto, A. B., Parry, C., Alfano, C. M., Padgett, L., Kent, E. E., Forsythe, L., Scoppa, S., Hachey, M., & Rowland, J. H. (2013) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-12-1356 · Cited by 670 · see citing works
Shortages of medicines: a complex global challenge
Gray, A., & Manasse, H. (2012) · Bulletin of the World Health Organization · doi:10.2471/blt.11.101303 · Cited by 136 · see citing works
Yang, C., Wu, L., Cai, W., Zhu, W., Shen, Q., Li, Z., & Fang, Y. (2016) · PLOS ONE · doi:10.1371/journal.pone.0165183 · Cited by 70 · see citing works
- Authors
- Chabner, B. A.
- Affiliations
- Massachusetts General Hospital (US)
- Corresponding author
- Chabner, Bruce A.
- ORCID
- Chabner, Bruce A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-12-08
- Volume
- 365
- Issue
- 23
- Pages
- 2147-2149
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2322979149
- Cited by
- 99
- References
- 0
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 4 · 2023: 4 · 2022: 1 · 2021: 3 · 2020: 8 · 2019: 5 · 2018: 4 · 2017: 4 · 2016: 7 · 2015: 7 · 2014: 14 · 2013: 18 · 2012: 16
- FWCI
- 40.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Healthcare Policy and Management
- Health Sciences › Health Professions › Health Information Management › Healthcare Regulation
- Keywords
- drug shortages, generic drugs, FDA regulation, pharmaceutical policy
- MeSH terms
- Anti-Bacterial Agents, Antineoplastic Agents, Drug Industry, Humans, Injections, United States, United States Food and Drug Administration, Drugs, Generic, Government Regulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
